XPD codon 751 polymorphism and risk of de novo and therapy-related AML
. | . | De novo AML cases . | . | t-AML cases, previous therapy . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Radiotherapy only . | . | Chemotherapy* . | . | ||||
. | Controls, no. (%) . | No. (%) . | OR (95% CI) . | No. (%) . | OR no. (95% CI) . | No. (%) . | OR (95% CI) . | ||||
| No. | 729 (100) | 420 (100) | NA | 40 (100) | NA | 51 (100) | NA | ||||
| XPD codon 751 | |||||||||||
| Lys/Lys | 293 (42) | 144 (38) | 1 | 19 (48) | 1 | 17 (33) | 1 | ||||
| Lys/Gln | 299 (43) | 176 (46) | 1.20 (0.91-1.57) | 19 (48) | 1.06 (0.54-2.12) | 21 (41) | 1.22 (0.63-2.36) | ||||
| Gln/Gln | 104 (15) | 63 (16) | 1.22 (0.84-1.78) | 2 (5) | 0.34 (0.07-1.51) | 13 (25) | 2.22 (1.04-4.74) | ||||
| ND | 33 | 37 | NA | 0 | NA | 0 | NA | ||||
. | . | De novo AML cases . | . | t-AML cases, previous therapy . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Radiotherapy only . | . | Chemotherapy* . | . | ||||
. | Controls, no. (%) . | No. (%) . | OR (95% CI) . | No. (%) . | OR no. (95% CI) . | No. (%) . | OR (95% CI) . | ||||
| No. | 729 (100) | 420 (100) | NA | 40 (100) | NA | 51 (100) | NA | ||||
| XPD codon 751 | |||||||||||
| Lys/Lys | 293 (42) | 144 (38) | 1 | 19 (48) | 1 | 17 (33) | 1 | ||||
| Lys/Gln | 299 (43) | 176 (46) | 1.20 (0.91-1.57) | 19 (48) | 1.06 (0.54-2.12) | 21 (41) | 1.22 (0.63-2.36) | ||||
| Gln/Gln | 104 (15) | 63 (16) | 1.22 (0.84-1.78) | 2 (5) | 0.34 (0.07-1.51) | 13 (25) | 2.22 (1.04-4.74) | ||||
| ND | 33 | 37 | NA | 0 | NA | 0 | NA | ||||
Odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression adjusting for sex and age at diagnosis in comparison with controls.
NA indicates not applicable; ND, not determined.
Chemotherapy alone, or in combination with radiotherapy.